Site KR82007

Seoul 152-703

1 studies enrolling now · 10 studies all time

What they study most

Advanced Hepatocellular Carcinoma, Advanced Solid Tumors, Leukemia, Acute Myeloid (AML), Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma, Metastatic Hormone Sensitive Prostate Cancer, Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer

Studies at this site

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study — Recruiting now
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer — Recruiting now
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer — Running, not enrolling
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer — Running, not enrolling
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer. — Running, not enrolling
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation — Completed
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide — Completed
A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma — Completed
A Study of ASP1951 in Subjects With Advanced Solid Tumors — Stopped early
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors — Completed